SEC EDGAROCT 21 min read$HIMS

Boughton Soleil sold $101K of HIMS

Boughton Soleil (Chief Legal Officer) sold 3,461 shares of Hims & Hers Health, Inc. (HIMS) at $29.17 ($0.10M total) on 2026-09-30 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Boughton Soleil

Published Oct 2, 2026, 8:31 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 2, 2026, 8:38 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$HIMS

Bearish

high confidence

Mentioned

$HIMS

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$HIMSBearishLow

Why it matters

A small insider sale may slightly depress the stock but is unlikely to move the market.

Market read

The filing provides fresh, albeit modest, information for traders monitoring insider activity.

What to watch

The 10b5-1 plan pre‑arranges sales, reducing the informational value of the transaction.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HIMSBearishHigh confidence

Context

Chief Legal Officer sold 3,461 shares for $100,957, reducing his stake to 300,809 shares.

Expected impact

likely modest pressure as the market prices in the insider sell.

Evidence & confidence

Form 4 filing is a primary source; the amount ($101K) is small but signals potential insider sentiment.

Market effects

Sector

Minimal impact on the broader telehealth sector.

Regional

No significant regional effect.

Global

Limited to Hims & Hers investors.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing and not indicative of negative outlook.

Key entities

Person
Boughton Soleil
Chief Legal Officer of Hims & Hers Health, Inc.
Company
Hims & Hers Health, Inc.
Provider of telehealth and wellness products.

Read at source ← All news

OCT 9

$HIMSHigh

HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here

Hims & Hers Health (HIMS) rose 7.36% to $30.13 on news of potential peptide regulation changes. The company plans to offer peptides by 2026. Analysts have mixed views, with Citi targeting $25 (17% downside) and Truist at $32. Q3 earnings on Nov 9, 2026, will be key.

investing.com2 min

SEP 25

$HIMSMedAI 8/10

Weekly Rundown: Abridge poised for broader VA expansion; Hims & Hers builds out AI-native care

Hims & Hers expanded its AI-powered care for weight loss patients, integrating AI into care workflows for personalized, continuous treatment. Abridge secured a VA contract for ambient AI, potentially deploying across 1,380 healthcare facilities. Epocrates and ScriptSave partnered to provide real-time prescription pricing. Remergify launched a membership-based virtual care platform. Penn State Health to deploy Epic EHR systemwide.

fiercehealthcare.com3 min

SEP 22

$HIMSMed

Hims & Hers Suit Spotlights Health Data-Sharing Privacy Risks

The FTC, along with California and Utah regulators, filed a lawsuit against Hims & Hers on July 29, alleging privacy risks related to health data-sharing. The complaint was filed in the U.S. District Court for the Northern District of California. This legal action highlights concerns over consumer data protection in the health sector.

law360.com1 min

SEP 19

$HIMSMed

Telehealth companies keep exposing their customers' medical data. What should they do?

The FTC sued Hims & Hers for allegedly disclosing customer health data, signing users up for hard-to-cancel subscriptions, and bypassing real-time doctor consultations. Hims disputes the claims. Experts note federal laws often don't apply to telehealth companies, leading to data sharing with advertisers. Recent studies found many telehealth services lack proper physician consultations, especially for GLP-1 drugs. State laws offer some protections, but enforcement is limited. Privacy experts reco

newsday.com2 min

SEP 18

$HIMSHighAI 8/10

Class-action lawsuit filed against Hims & Hers following FTC complaint

A class-action lawsuit was filed against Hims & Hers (HIMS) on behalf of investors who acquired securities between 4 August 2025 and 29 July 2026, following an FTC complaint. The FTC alleges deceptive billing and unlawful sharing of health information. HIMS shares fell 14.73% on the news, closing at $25.00. The company denies the allegations.

dig.watch2 min

SEP 17